Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KMT2C mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

KMT2C mutation	Colorectal Cancer	KMT2C mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Solid Tumor	KMT2C mutation	Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Non Small Cell Lung Cancer	KMT2C mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Colorectal Cancer	KMT2C mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Hepatocellular Cancer	KMT2C mutation	Hepatocellular Cancer	PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials PD1 inhibitor + lenvatinib Sensitive : C3	PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials PD1 inhibitor + lenvatinib Sensitive : C3
KMT2C mutation	Renal Cell Carcinoma	KMT2C mutation	Renal Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Melanoma	KMT2C mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Bladder Cancer	KMT2C mutation	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3